First-Line Dabrafenib plus Trametinib Has Activity in BRAFV600E NSCLC [Research Watch]

Dabrafenib plus trametinib achieves responses in 64% of patients with metastatic BRAF^V600E NSCLC.

from Cancer via ola Kala on Inoreader http://ift.tt/2wJkndU
via IFTTT